Close Menu

NEW YORK — Avellino Labs said today that its Menlo Park, California facility has received CLIA certification, enabling the company to receive and process samples for its AvaGen test for keratoconus and corneal dystrophies.

AvaGen is a next-generation sequencing-based test designed to analyze 1,000 variants across 75 genes to determine the risk of keratoconus, as well as over 70 TGFBI mutations of the transforming growth factor beta induced — or TGFBI — gene for detecting the presence of corneal dystrophies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.